GERN $3.75 acting nicely-
I believe GERN is one of the best plays out there. That is, after the ADCOM recommended approval of Imetelstat on March 14, with a 12-2 vote, chance of FDA approval is 97% according to JAMA studies. I believe GERN will be over $6 if FDA approves on June 16. As I've posted many times, after crunching the numbers, I feel GERN will post $.60+ fully taxed and diluted on $1B in revenues, which I believe will happen by 2028. GERN estimates $2B+/year by 2030. This estimate doesn't include the use of Imetelstat for Myelofibrosis, which is in phase 3 studies by GERN. So huge potential for GERN IMO
